Investor Presentaiton
Acquire approved and development-stage royalties
•
Approved Products (2)
Predictable and de-risked
cash flows
•
Growth from increased
penetration
Additional upside from new
indications/geographies
Development-Stage Products
Broad landscape of
opportunities
.
Require strong proof-of-
concept data
Significant upside potential
ROYALTY PHARMA
Status at Acquisition (1)
Total - ~$24bn
Development-
Stage Products
~$11bn, 45%
Approved
Products
~$13bn, 55%
Current Status(1)
Development-Stage Products
$3bn, 13%
Not Approved
$1bn, 4% (2)
$6.7bn or 63% of
Development-Stage
Product Acquisitions
Are Now Approved
Approved
Products
$20bn, 83%
1. Reflects cash deployed for royalty acquisitions from 2012 through Q4 2022. Also include the January 2023 lonis transaction.
2. Not approved includes investments in gantenerumab, otilimab, BCX9930, vosaroxin, palbociclib and Merck KgaA's anti-IL17 nanobody M1095.
Approved
Since Acquisition
Bosulif
Evrysdi
Prisdiplam
60mg
pride forel
imbruvică
NurtecMODT
TAZVERIK
Tecfidera.
trikafta
TRODELVY™
107View entire presentation